1
|
Xu L, Wu Y, Shen X, Zhou L, Lu Y, Teng Z, Du J, Ding M, Han H, Niu T. Exploring the biological basis of CT imaging features in pancreatic neuroendocrine tumors: a two-center study. Phys Med Biol 2024; 69:125013. [PMID: 38810631 DOI: 10.1088/1361-6560/ad51c7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Accepted: 05/29/2024] [Indexed: 05/31/2024]
Abstract
Objective.Medical imaging offered a non-invasive window to visualize tumors, with radiomics transforming these images into quantitative data for tumor phenotyping. However, the intricate web linking imaging features, clinical endpoints, and tumor biology was mostly uncharted. This study aimed to unravel the connections between CT imaging features and clinical characteristics, including tumor histopathological grading, clinical stage, and endocrine symptoms, alongside immunohistochemical markers of tumor cell growth, such as the Ki-67 index and nuclear mitosis rate.Approach.We conducted a retrospective analysis of data from 137 patients with pancreatic neuroendocrine tumors who had undergone contrast-enhanced CT scans across two institutions. Our study focused on three clinical factors: pathological grade, clinical stage, and endocrine symptom status, in addition to two immunohistochemical markers: the Ki-67 index and the rate of nuclear mitosis. We computed both predefined (2D and 3D) and learning-based features (via sparse autoencoder, or SAE) from the scans. To unearth the relationships between imaging features, clinical factors, and immunohistochemical markers, we employed the Spearman rank correlation along with the Benjamini-Hochberg method. Furthermore, we developed and validated radiomics signatures to foresee these clinical factors.Main results.The 3D imaging features showed the strongest relationships with clinical factors and immunohistochemical markers. For the association with pathological grade, the mean absolute value of the correlation coefficient (CC) of 2D, SAE, and 3D features was 0.3318 ± 0.1196, 0.2149 ± 0.0361, and 0.4189 ± 0.0882, respectively. While for the association with Ki-67 index and rate of nuclear mitosis, the 3D features also showed higher correlations, with CC as 0.4053 ± 0.0786 and 0.4061 ± 0.0806. In addition, the 3D feature-based signatures showed optimal performance in clinical factor prediction.Significance.We found relationships between imaging features, clinical factors, and immunohistochemical markers. The 3D features showed higher relationships with clinical factors and immunohistochemical markers.
Collapse
Affiliation(s)
- Lei Xu
- Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, People's Republic of China
| | - Yan Wu
- Department of Orthopaedics, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
| | - Xiaoyong Shen
- Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
| | - Luping Zhou
- Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China
| | - Yongkai Lu
- Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China
| | - Ze Teng
- Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
| | - Jichen Du
- Peking University Aerospace School of Clinical Medicine, Aerospace Center Hospital, Beijing, People's Republic of China
| | - Mingchao Ding
- Peking University Aerospace School of Clinical Medicine, Aerospace Center Hospital, Beijing, People's Republic of China
| | - Hongbin Han
- Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
- Beijing Key Laboratory of Magnetic Resonance Imaging Devices and Technology, Peking University Third Hospital, Beijing, People's Republic of China
| | - Tianye Niu
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, People's Republic of China
- Peking University Aerospace School of Clinical Medicine, Aerospace Center Hospital, Beijing, People's Republic of China
| |
Collapse
|
2
|
He Y, Yang M, Hou R, Ai S, Nie T, Chen J, Hu H, Guo X, Liu Y, Yuan Z. Preoperative prediction of perineural invasion and lymphovascular invasion with CT radiomics in gastric cancer. Eur J Radiol Open 2024; 12:100550. [PMID: 38314183 PMCID: PMC10837067 DOI: 10.1016/j.ejro.2024.100550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 01/15/2024] [Accepted: 01/15/2024] [Indexed: 02/06/2024] Open
Abstract
Objectives To determine whether contrast-enhanced CT radiomics features can preoperatively predict lymphovascular invasion (LVI) and perineural invasion (PNI) in gastric cancer (GC). Methods A total of 148 patients were included in the LVI group, and 143 patients were included in the PNI group. Three predictive models were constructed, including clinical, radiomics, and combined models. A nomogram was developed with clinical risk factors to predict LVI and PNI status. The predictive performance of the three models was mainly evaluated using the mean area under the curve (AUC). The performance of three predictive models was assessed concerning calibration and clinical usefulness. Results In the LVI group, the predictive power of the combined model (AUC=0.871, 0.822) outperformed the clinical model (AUC=0.792, 0.728) and the radiomics model (AUC=0.792, 0.728) in both the training and testing cohorts. In the PNI group, the combined model (AUC=0.834, 0.828) also had better predictive power than the clinical model (AUC=0.764, 0.632) and the radiomics model (AUC=0.764, 0.632) in both the training and testing cohorts. The combined models also showed good calibration and clinical usefulness for LVI and PNI prediction. Conclusion CECT-based radiomics analysis might serve as a non-invasive method to predict LVI and PNI status in GC.
Collapse
Affiliation(s)
- Yaoyao He
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Miao Yang
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Rong Hou
- Department of Patholoogy, Suizhou Hospital Affiliated to Hubei Medical College, 441300, PR China
| | - Shuangquan Ai
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Tingting Nie
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Jun Chen
- Bayer Healthcare, Wuhan, PR China
| | - Huaifei Hu
- College of Biomedical Engineering, South-Central Minzu University, Wuhan 430074, PR China
| | - Xiaofang Guo
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Yulin Liu
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| | - Zilong Yuan
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China
| |
Collapse
|
3
|
Xie H, Huang W, Li S, Huang M, Luo C, Li S, Cui C, Ma H, Li H, Liu L, Wang X, Fu G. Radiomics-based lymph nodes prognostic models from three MRI regions in nasopharyngeal carcinoma. Heliyon 2024; 10:e31557. [PMID: 38803981 PMCID: PMC11128517 DOI: 10.1016/j.heliyon.2024.e31557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 05/17/2024] [Accepted: 05/17/2024] [Indexed: 05/29/2024] Open
Abstract
Accurate prediction of the prognosis of nasopharyngeal carcinoma (NPC) is important for treatment. Lymph nodes metastasis is an important predictor for distant failure and regional recurrence in patients with NPC. Traditionally, subjective radiological evaluation increases concerns regarding the accuracy and consistency of predictions. Radiomics is an objective and quantitative evaluation algorithm for medical images. This retrospective analysis was conducted based on the data of 729 patients newly diagnosed with NPC without distant metastases to evaluate the performance of radiomics pretreatment using magnetic resonance imaging (MRI)-determined metastatic lymph nodes models to predict NPC prognosis with three delineation methods. Radiomics features were extracted from all lymph nodes (ALN), largest lymph node (LLN), and largest slice of the largest lymph node (LSLN) to generate three radiomics signatures. The radiomics signatures, clinical model, and radiomics-clinic merged models were developed in training cohort for predicting overall survival (OS). The results showed that LSLN signature with clinical factors predicted OS with high accuracy and robustness using pretreatment MR-determined metastatic lymph nodes (C-index [95 % confidence interval]: 0.762[0.760-0.763]), providing a new tool for treatment planning in NPC.
Collapse
Affiliation(s)
- Hui Xie
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Wenjie Huang
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Shaolong Li
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Manqian Huang
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Chao Luo
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Shuqi Li
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Chunyan Cui
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Huali Ma
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Haojiang Li
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Lizhi Liu
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Xiaoyi Wang
- Department of Radiology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China
| | - Gui Fu
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
| |
Collapse
|
4
|
Jia W, Li F, Cui Y, Wang Y, Dai Z, Yan Q, Liu X, Li Y, Chang H, Zeng Q. Deep Learning Radiomics Model of Contrast-Enhanced CT for Differentiating the Primary Source of Liver Metastases. Acad Radiol 2024:S1076-6332(24)00221-6. [PMID: 38702214 DOI: 10.1016/j.acra.2024.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Revised: 04/05/2024] [Accepted: 04/11/2024] [Indexed: 05/06/2024]
Abstract
RATIONALE AND OBJECTIVES To develop and validate a deep learning radiomics (DLR) model based on contrast-enhanced computed tomography (CT) to identify the primary source of liver metastases. MATERIALS AND METHODS In total, 657 liver metastatic lesions, including breast cancer (BC), lung cancer (LC), colorectal cancer (CRC), gastric cancer (GC), and pancreatic cancer (PC), from 428 patients were collected at three clinical centers from January 2018 to October 2023 series. The lesions were randomly assigned to the training and validation sets in a 7:3 ratio. An additional 112 lesions from 61 patients at another clinical center served as an external test set. A DLR model based on contrast-enhanced CT of the liver was developed to distinguish the five pathological types of liver metastases. Stepwise classification was performed to improve the classification efficiency of the model. Lesions were first classified as digestive tract cancer (DTC) and non-digestive tract cancer (non-DTC). DTCs were divided into CRC, GC, and PC and non-DTCs were divided into LC and BC. To verify the feasibility of the DLR model, we trained classical machine learning (ML) models as comparison models. Model performance was evaluated using accuracy (ACC) and area under the receiver operating characteristic curve (AUC). RESULTS The classification model constructed by the DLR algorithm showed excellent performance in the classification task compared to ML models. Among the five categories task, highest ACC and average AUC were achieved at 0.563 and 0.796 in the validation set, respectively. In the DTC and non-DTC and the LC and BC classification tasks, AUC was achieved at 0.907 and 0.809 and ACC was achieved at 0.843 and 0.772, respectively. In the CRC, GC, and PC classification task, ACC and average AUC were the highest, at 0.714 and 0.811, respectively. CONCLUSION The DLR model is an effective method for identifying the primary source of liver metastases.
Collapse
Affiliation(s)
- Wenjing Jia
- Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China; Shandong First Medical University, Jinan, China.
| | - Fuyan Li
- Department of Radiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.
| | - Yi Cui
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, China.
| | - Yong Wang
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
| | - Zhengjun Dai
- Scientific Research Department, Huiying Medical Technology Co., Ltd, Beijing, China.
| | - Qingqing Yan
- Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
| | - Xinhui Liu
- Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
| | - Yuting Li
- Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
| | - Huan Chang
- Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
| | - Qingshi Zeng
- Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
| |
Collapse
|
5
|
Liu NJ, Liu MS, Tian W, Zhai YN, Lv WL, Wang T, Guo SL. The value of machine learning based on CT radiomics in the preoperative identification of peripheral nerve invasion in colorectal cancer: a two-center study. Insights Imaging 2024; 15:101. [PMID: 38578423 PMCID: PMC10997560 DOI: 10.1186/s13244-024-01664-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 03/04/2024] [Indexed: 04/06/2024] Open
Abstract
BACKGROUND We aimed to explore the application value of various machine learning (ML) algorithms based on multicenter CT radiomics in identifying peripheral nerve invasion (PNI) of colorectal cancer (CRC). METHODS A total of 268 patients with colorectal cancer who underwent CT examination in two hospitals from January 2016 to December 2022 were considered. Imaging and clinicopathological data were collected through the Picture Archiving and Communication System (PACS). The Feature Explorer software (FAE) was used to identify the peripheral nerve invasion of colorectal patients in center 1, and the best feature selection and classification channels were selected. Finally, the best feature selection and classifier pipeline were verified in center 2. RESULTS The six-feature models using RFE feature selection and GP classifier had the highest AUC values, which were 0.610, 0.699, and 0.640, respectively. FAE generated a more concise model based on one feature (wavelet-HLL-glszm-LargeAreaHighGrayLevelEmphasis) and achieved AUC values of 0.614 and 0.663 on the validation and test sets, respectively, using the "one standard error" rule. Using ANOVA feature selection, the GP classifier had the best AUC value in a one-feature model, with AUC values of 0.611, 0.663, and 0.643 on the validation, internal test, and external test sets, respectively. Similarly, when using the "one standard error" rule, the model based on one feature (wave-let-HLL-glszm-LargeAreaHighGrayLevelEmphasis) achieved AUC values of 0.614 and 0.663 on the validation and test sets, respectively. CONCLUSIONS Combining artificial intelligence and radiomics features is a promising approach for identifying peripheral nerve invasion in colorectal cancer. This innovative technique holds significant potential for clinical medicine, offering broader application prospects in the field. CRITICAL RELEVANCE STATEMENT The multi-channel ML method based on CT radiomics has a simple operation process and can be used to assist in the clinical screening of patients with CRC accompanied by PNI. KEY POINTS • Multi-channel ML in the identification of peripheral nerve invasion in CRC. • Multi-channel ML method based on CT-radiomics can detect the PNI of CRC. • Early preoperative identification of PNI in CRC is helpful to improve the formulation of treatment strategies and the prognosis of patients.
Collapse
Affiliation(s)
- Nian-Jun Liu
- The First School of Clinical Medical, Lanzhou University, LanzhouGansu, 73000, China
- Department of Radiology, the First Hospital of Lanzhou University, LanzhouGansu, 73000, China
- Intelligent Imaging Medical Engineering Research Center of Gansu Province, LanzhouGansu, 73000, China
- Accurate Image Collaborative Innovation International Science and Technology Cooperation Base of Gansu Province, LanzhouGansu, 73000, China
- Gansu Province clinical research center for radiology imaging, LanzhouGansu, 73000, China
| | - Mao-Sen Liu
- Lichuan People's Hospital, Lichuan, 445400, Hubei, China
| | - Wei Tian
- The First School of Clinical Medical, Lanzhou University, LanzhouGansu, 73000, China
- Department of Radiology, the First Hospital of Lanzhou University, LanzhouGansu, 73000, China
- Intelligent Imaging Medical Engineering Research Center of Gansu Province, LanzhouGansu, 73000, China
- Accurate Image Collaborative Innovation International Science and Technology Cooperation Base of Gansu Province, LanzhouGansu, 73000, China
- Gansu Province clinical research center for radiology imaging, LanzhouGansu, 73000, China
| | - Ya-Nan Zhai
- The First School of Clinical Medical, Lanzhou University, LanzhouGansu, 73000, China
- Department of Radiology, the First Hospital of Lanzhou University, LanzhouGansu, 73000, China
- Intelligent Imaging Medical Engineering Research Center of Gansu Province, LanzhouGansu, 73000, China
- Accurate Image Collaborative Innovation International Science and Technology Cooperation Base of Gansu Province, LanzhouGansu, 73000, China
- Gansu Province clinical research center for radiology imaging, LanzhouGansu, 73000, China
| | - Wei-Long Lv
- The First School of Clinical Medical, Lanzhou University, LanzhouGansu, 73000, China
- Department of Radiology, the First Hospital of Lanzhou University, LanzhouGansu, 73000, China
- Intelligent Imaging Medical Engineering Research Center of Gansu Province, LanzhouGansu, 73000, China
- Accurate Image Collaborative Innovation International Science and Technology Cooperation Base of Gansu Province, LanzhouGansu, 73000, China
- Gansu Province clinical research center for radiology imaging, LanzhouGansu, 73000, China
| | - Tong Wang
- The First School of Clinical Medical, Lanzhou University, LanzhouGansu, 73000, China
- Department of Radiology, the First Hospital of Lanzhou University, LanzhouGansu, 73000, China
- Intelligent Imaging Medical Engineering Research Center of Gansu Province, LanzhouGansu, 73000, China
- Accurate Image Collaborative Innovation International Science and Technology Cooperation Base of Gansu Province, LanzhouGansu, 73000, China
- Gansu Province clinical research center for radiology imaging, LanzhouGansu, 73000, China
| | - Shun-Lin Guo
- The First School of Clinical Medical, Lanzhou University, LanzhouGansu, 73000, China.
- Department of Radiology, the First Hospital of Lanzhou University, LanzhouGansu, 73000, China.
- Intelligent Imaging Medical Engineering Research Center of Gansu Province, LanzhouGansu, 73000, China.
- Accurate Image Collaborative Innovation International Science and Technology Cooperation Base of Gansu Province, LanzhouGansu, 73000, China.
- Gansu Province clinical research center for radiology imaging, LanzhouGansu, 73000, China.
| |
Collapse
|
6
|
Prior O, Macarro C, Navarro V, Monreal C, Ligero M, Garcia-Ruiz A, Serna G, Simonetti S, Braña I, Vieito M, Escobar M, Capdevila J, Byrne AT, Dienstmann R, Toledo R, Nuciforo P, Garralda E, Grussu F, Bernatowicz K, Perez-Lopez R. Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer. Radiol Artif Intell 2024; 6:e230118. [PMID: 38294307 PMCID: PMC10982821 DOI: 10.1148/ryai.230118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 10/18/2023] [Accepted: 01/07/2024] [Indexed: 02/01/2024]
Abstract
Purpose To identify precise three-dimensional radiomics features in CT images that enable computation of stable and biologically meaningful habitats with machine learning for cancer heterogeneity assessment. Materials and Methods This retrospective study included 2436 liver or lung lesions from 605 CT scans (November 2010-December 2021) in 331 patients with cancer (mean age, 64.5 years ± 10.1 [SD]; 185 male patients). Three-dimensional radiomics were computed from original and perturbed (simulated retest) images with different combinations of feature computation kernel radius and bin size. The lower 95% confidence limit (LCL) of the intraclass correlation coefficient (ICC) was used to measure repeatability and reproducibility. Precise features were identified by combining repeatability and reproducibility results (LCL of ICC ≥ 0.50). Habitats were obtained with Gaussian mixture models in original and perturbed data using precise radiomics features and compared with habitats obtained using all features. The Dice similarity coefficient (DSC) was used to assess habitat stability. Biologic correlates of CT habitats were explored in a case study, with a cohort of 13 patients with CT, multiparametric MRI, and tumor biopsies. Results Three-dimensional radiomics showed poor repeatability (LCL of ICC: median [IQR], 0.442 [0.312-0.516]) and poor reproducibility against kernel radius (LCL of ICC: median [IQR], 0.440 [0.33-0.526]) but excellent reproducibility against bin size (LCL of ICC: median [IQR], 0.929 [0.853-0.988]). Twenty-six radiomics features were precise, differing in lung and liver lesions. Habitats obtained with precise features (DSC: median [IQR], 0.601 [0.494-0.712] and 0.651 [0.52-0.784] for lung and liver lesions, respectively) were more stable than those obtained with all features (DSC: median [IQR], 0.532 [0.424-0.637] and 0.587 [0.465-0.703] for lung and liver lesions, respectively; P < .001). In the case study, CT habitats correlated quantitatively and qualitatively with heterogeneity observed in multiparametric MRI habitats and histology. Conclusion Precise three-dimensional radiomics features were identified on CT images that enabled tumor heterogeneity assessment through stable tumor habitat computation. Keywords: CT, Diffusion-weighted Imaging, Dynamic Contrast-enhanced MRI, MRI, Radiomics, Unsupervised Learning, Oncology, Liver, Lung Supplemental material is available for this article. © RSNA, 2024 See also the commentary by Sagreiya in this issue.
Collapse
Affiliation(s)
- Olivia Prior
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Carlos Macarro
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Víctor Navarro
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Camilo Monreal
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Marta Ligero
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Alonso Garcia-Ruiz
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Garazi Serna
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Sara Simonetti
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Irene Braña
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Maria Vieito
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Manuel Escobar
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Jaume Capdevila
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Annette T. Byrne
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Rodrigo Dienstmann
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Rodrigo Toledo
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Paolo Nuciforo
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Elena Garralda
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | - Francesco Grussu
- From the Radiomics Group, Vall d’Hebron Institute of Oncology,
Carrer de Natzaret 115–117, Barcelona 08035, Spain (O.P., C. Macarro, C.
Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall
d’Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular
Pathology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
(G.S., S.S., P.N.); Department of Medical Oncology, Vall d’Hebron
University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular
Therapeutic Research Unit, Vall d’Hebron Institute of Oncology,
Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall
d’Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and
Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO),
Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre
for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
(A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland
(A.T.B.)
| | | | | |
Collapse
|
7
|
Brandenberger D, White LM. Radiomics in Musculoskeletal Tumors. Semin Musculoskelet Radiol 2024; 28:49-61. [PMID: 38330970 DOI: 10.1055/s-0043-1776428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2024]
Abstract
Sarcomas are heterogeneous rare tumors predominantly affecting the musculoskeletal (MSK) system. Due to significant variations in their natural history and variable response to conventional treatments, the discovery of novel diagnostic and prognostic biomarkers to guide therapeutic decision-making is an active and ongoing field of research. As new cellular, molecular, and metabolic biomarkers continue to be discovered, quantitative radiologic imaging is becoming increasingly important in sarcoma management. Radiomics offers the potential for discovering novel imaging diagnostic and predictive biomarkers using standard-of-care medical imaging. In this review, we detail the core concepts of radiomics and the application of radiomics to date in MSK sarcoma research. Also described are specific challenges related to radiomic studies, as well as viewpoints on clinical adoption and future perspectives in the field.
Collapse
Affiliation(s)
- Daniel Brandenberger
- Department of Medical Imaging, Musculoskeletal Imaging, University of Toronto, Toronto, Ontario, Canada
- Institut für Radiologie und Nuklearmedizin, Kantonsspital Baselland, Liestal, Switzerland
- Toronto Joint Department of Medical Imaging, University Health Network, Sinai Health System, and Women's College Hospital, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Lawrence M White
- Department of Medical Imaging, Musculoskeletal Imaging, University of Toronto, Toronto, Ontario, Canada
- Toronto Joint Department of Medical Imaging, University Health Network, Sinai Health System, and Women's College Hospital, Mount Sinai Hospital, Toronto, Ontario, Canada
| |
Collapse
|
8
|
Liu X, Xu Y, Wang G, Ma X, Lin M, Zuo Y, Li W. Bronchiolar adenoma/ciliated muconodular papillary tumour: advancing clinical, pathological, and imaging insights for future perspectives. Clin Radiol 2024; 79:85-93. [PMID: 38049359 DOI: 10.1016/j.crad.2023.10.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 10/11/2023] [Accepted: 10/30/2023] [Indexed: 12/06/2023]
Abstract
Bronchiolar adenoma/ciliated muconodular papillary tumour (BA/CMPT) is a benign peripheral lung tumour composed of bilayered bronchiolar-type epithelium containing a continuous basal cell layer; however, the similarities in imaging and tissue biopsy findings at histopathology between BA/CMPT and malignant tumours, including lung adenocarcinoma, pose significant challenges in accurately diagnosing BA/CMPT preoperatively. This difficulty in differentiation often results in misdiagnosis and unnecessary overtreatment. The objective of this article is to provide a comprehensive and systematic review of BA/CMPT, encompassing its clinical manifestations, pathological basis, imaging features, and differential diagnosis. By enhancing healthcare professionals' understanding of this disease, we aim to improve the accuracy of preoperative BA/CMPT diagnosis. This improvement is crucial for the development of appropriate therapeutic strategies and the overall improvement of patient prognosis.
Collapse
Affiliation(s)
- X Liu
- Medical School, Kunming University of Science and Technology, Kunming 650500, P.R. China; Department of Radiology, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China
| | - Y Xu
- Department of Pathology, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China
| | - G Wang
- Department of Radiology, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China
| | - X Ma
- Department of Scientific Research, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China
| | - M Lin
- Medical School, Kunming University of Science and Technology, Kunming 650500, P.R. China; Department of Radiology, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China
| | - Y Zuo
- Department of Radiology, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China.
| | - W Li
- Department of Radiology, The First People's Hospital of Yunnan Province, Kunming 650032, Yunnan, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China.
| |
Collapse
|
9
|
Li Y, Yang L, Gu X, Wang Q, Shi G, Zhang A, Yue M, Wang M, Ren J. Computed tomography radiomics identification of T1-2 and T3-4 stages of esophageal squamous cell carcinoma: two-dimensional or three-dimensional? Abdom Radiol (NY) 2024; 49:288-300. [PMID: 37843576 PMCID: PMC10789855 DOI: 10.1007/s00261-023-04070-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 09/15/2023] [Accepted: 09/19/2023] [Indexed: 10/17/2023]
Abstract
BACKGROUND To evaluate two-dimensional (2D) and three-dimensional (3D) computed tomography (CT) radiomics analysis for the T stage of esophageal squamous cell carcinoma (ESCC). METHODS 398 patients with pathologically confirmed ESCC were divided into training and testing sets. All patients underwent chest CT scans preoperatively. For each tumor, based on CT images, a 2D region of interest (ROI) was outlined on the largest cross-sectional area, and a 3D ROI was outlined layer by layer on each section of the tumor. The radiomics platform was used for feature extraction. For feature selection, stepwise logistic regression was used. The receiver operating characteristic (ROC) curve was used to assess the diagnostic performance of the 2D radiomics model versus the 3D radiomics model. The differences were compared using the DeLong test. The value of the clinical utility of the two radiomics models was evaluated. RESULTS 1595 radiomics features were extracted. After screening, two radiomics models were constructed. In the training set, the difference between the area under the curve (AUC) of the 2D radiomics model (AUC = 0.831) and the 3D radiomics model (AUC = 0.830) was not statistically significant (p = 0.973). In the testing set, the difference between the AUC of the 2D radiomics model (AUC = 0.807) and the 3D radiomics model (AUC = 0.797) was also not statistically significant (p = 0.748). A 2D model was equally useful as a 3D model in clinical situations. CONCLUSION The performance of 2D radiomics model is comparable to that of 3D radiomics model in distinguishing between the T1-2 and T3-4 stages of ESCC. In addition, 2D radiomics model may be a more feasible option due to the shorter time required for segmenting the ROI.
Collapse
Affiliation(s)
- Yang Li
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Li Yang
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Xiaolong Gu
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China.
| | - Qi Wang
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Gaofeng Shi
- Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Andu Zhang
- Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Meng Yue
- Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Mingbo Wang
- Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, People's Republic of China
| | - Jialiang Ren
- GE Healthcare China, Beijing, 100176, People's Republic of China
| |
Collapse
|
10
|
Abdoli N, Zhang K, Gilley P, Chen X, Sadri Y, Thai T, Dockery L, Moore K, Mannel R, Qiu Y. Evaluating the Effectiveness of 2D and 3D CT Image Features for Predicting Tumor Response to Chemotherapy. Bioengineering (Basel) 2023; 10:1334. [PMID: 38002458 PMCID: PMC10669238 DOI: 10.3390/bioengineering10111334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 11/08/2023] [Accepted: 11/09/2023] [Indexed: 11/26/2023] Open
Abstract
Background and Objective: 2D and 3D tumor features are widely used in a variety of medical image analysis tasks. However, for chemotherapy response prediction, the effectiveness between different kinds of 2D and 3D features are not comprehensively assessed, especially in ovarian-cancer-related applications. This investigation aims to accomplish such a comprehensive evaluation. Methods: For this purpose, CT images were collected retrospectively from 188 advanced-stage ovarian cancer patients. All the metastatic tumors that occurred in each patient were segmented and then processed by a set of six filters. Next, three categories of features, namely geometric, density, and texture features, were calculated from both the filtered results and the original segmented tumors, generating a total of 1403 and 1595 features for the 2D and 3D tumors, respectively. In addition to the conventional single-slice 2D and full-volume 3D tumor features, we also computed the incomplete-3D tumor features, which were achieved by sequentially adding one individual CT slice and calculating the corresponding features. Support vector machine (SVM)-based prediction models were developed and optimized for each feature set. Five-fold cross-validation was used to assess the performance of each individual model. Results: The results show that the 2D feature-based model achieved an AUC (area under the ROC curve (receiver operating characteristic)) of 0.84 ± 0.02. When adding more slices, the AUC first increased to reach the maximum and then gradually decreased to 0.86 ± 0.02. The maximum AUC was yielded when adding two adjacent slices, with a value of 0.91 ± 0.01. Conclusions: This initial result provides meaningful information for optimizing machine learning-based decision-making support tools in the future.
Collapse
Affiliation(s)
- Neman Abdoli
- School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA; (N.A.); (K.Z.); (Y.S.)
| | - Ke Zhang
- School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA; (N.A.); (K.Z.); (Y.S.)
- Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Patrik Gilley
- School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA; (N.A.); (K.Z.); (Y.S.)
| | - Xuxin Chen
- School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA; (N.A.); (K.Z.); (Y.S.)
| | - Youkabed Sadri
- School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA; (N.A.); (K.Z.); (Y.S.)
| | - Theresa Thai
- Department of Radiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA;
| | - Lauren Dockery
- Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Kathleen Moore
- Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Robert Mannel
- Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Yuchen Qiu
- School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA; (N.A.); (K.Z.); (Y.S.)
| |
Collapse
|
11
|
Zhang X, Zhang G, Qiu X, Yin J, Tan W, Yin X, Yang H, Liao L, Wang H, Zhang Y. Radiomics under 2D regions, 3D regions, and peritumoral regions reveal tumor heterogeneity in non-small cell lung cancer: a multicenter study. LA RADIOLOGIA MEDICA 2023; 128:1079-1092. [PMID: 37486526 DOI: 10.1007/s11547-023-01676-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Accepted: 06/29/2023] [Indexed: 07/25/2023]
Abstract
PURPOSE Lung cancer has significant genetic and phenotypic heterogeneity, leading to poor prognosis. Radiomic features have emerged as promising predictors of the tumor phenotype. However, the role of underlying information surrounding the cancer remains unclear. MATERIALS AND METHODS We conducted a retrospective study of 508 patients with NSCLC from three institutions. Radiomics models were built using features from six tumor regions and seven classifiers to predict three prognostically significant tumor phenotypes. The models were evaluated and interpreted by the mean area under the receiver operating characteristic curve (AUC) under nested cross-validation and Shapley values. The best-performing predictive models corresponding to six tumor regions and three tumor phenotypes were identified for further comparative analysis. In addition, we designed five experiments with different voxel spacing to assess the sensitivity of the experimental results to the spatial resolution of the voxels. RESULTS Our results demonstrated that models based on 2D, 3D, and peritumoral region features yielded mean AUCs and 95% confidence intervals of 0.759 and [0.747-0.771] for lymphovascular invasion, 0.889 and [0.882-0.896] for pleural invasion, and 0.839 and [0.829-0.849] for T-staging in the testing cohort, which was significantly higher than all other models. Similar results were obtained for the model combining the three regional features at five voxel spacings. CONCLUSION Our study revealed the predictive role of the developed methods with multi-regional features for the preoperative assessment of prognostic factors in NSCLC. The analysis of different voxel spacing and model interpretability strengthens the experimental findings and contributes to understanding the biological significance of the radiological phenotype.
Collapse
Affiliation(s)
- Xingping Zhang
- Cyberspace Institute of Advanced Technology, Guangzhou University, Guangzhou, 510006, China
- Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC, 3011, Australia
- Department of New Networks, Peng Cheng Laboratory, Shenzhen, 518000, China
| | - Guijuan Zhang
- Department of Respiratory and Critical Care, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China
| | - Xingting Qiu
- Department of Radiology, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China
| | - Jiao Yin
- Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC, 3011, Australia
| | - Wenjun Tan
- Key Laboratory of Intelligent Computing in Medical Image, Ministry of Education, Northeastern University, Shenyang, 110189, China
| | - Xiaoxia Yin
- Cyberspace Institute of Advanced Technology, Guangzhou University, Guangzhou, 510006, China
| | - Hong Yang
- Cyberspace Institute of Advanced Technology, Guangzhou University, Guangzhou, 510006, China
| | - Liefa Liao
- School of Information Engineering, Jiangxi University of Science and Technology, Ganzhou, 341000, China
| | - Hua Wang
- Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC, 3011, Australia.
| | - Yanchun Zhang
- Cyberspace Institute of Advanced Technology, Guangzhou University, Guangzhou, 510006, China.
- Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC, 3011, Australia.
- Department of New Networks, Peng Cheng Laboratory, Shenzhen, 518000, China.
| |
Collapse
|
12
|
Fiz F, Rossi N, Langella S, Ruzzenente A, Serenari M, Ardito F, Cucchetti A, Gallo T, Zamboni G, Mosconi C, Boldrini L, Mirarchi M, Cirillo S, De Bellis M, Pecorella I, Russolillo N, Borzi M, Vara G, Mele C, Ercolani G, Giuliante F, Ravaioli M, Guglielmi A, Ferrero A, Sollini M, Chiti A, Torzilli G, Ieva F, Viganò L. Radiomic Analysis of Intrahepatic Cholangiocarcinoma: Non-Invasive Prediction of Pathology Data: A Multicenter Study to Develop a Clinical-Radiomic Model. Cancers (Basel) 2023; 15:4204. [PMID: 37686480 PMCID: PMC10486795 DOI: 10.3390/cancers15174204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 08/08/2023] [Accepted: 08/16/2023] [Indexed: 09/10/2023] Open
Abstract
Standard imaging cannot assess the pathology details of intrahepatic cholangiocarcinoma (ICC). We investigated whether CT-based radiomics may improve the prediction of tumor characteristics. All consecutive patients undergoing liver resection for ICC (2009-2019) in six high-volume centers were evaluated for inclusion. On the preoperative CT, we segmented the ICC (Tumor-VOI, i.e., volume-of-interest) and a 5-mm parenchyma rim around the tumor (Margin-VOI). We considered two types of pathology data: tumor grading (G) and microvascular invasion (MVI). The predictive models were internally validated. Overall, 244 patients were analyzed: 82 (34%) had G3 tumors and 139 (57%) had MVI. For G3 prediction, the clinical model had an AUC = 0.69 and an Accuracy = 0.68 at internal cross-validation. The addition of radiomic features extracted from the portal phase of CT improved the model performance (Clinical data+Tumor-VOI: AUC = 0.73/Accuracy = 0.72; +Tumor-/Margin-VOI: AUC = 0.77/Accuracy = 0.77). Also for MVI prediction, the addition of portal phase radiomics improved the model performance (Clinical data: AUC = 0.75/Accuracy = 0.70; +Tumor-VOI: AUC = 0.82/Accuracy = 0.73; +Tumor-/Margin-VOI: AUC = 0.82/Accuracy = 0.75). The permutation tests confirmed that a combined clinical-radiomic model outperforms a purely clinical one (p < 0.05). The addition of the textural features extracted from the arterial phase had no impact. In conclusion, the radiomic features of the tumor and peritumoral tissue extracted from the portal phase of preoperative CT improve the prediction of ICC grading and MVI.
Collapse
Affiliation(s)
- Francesco Fiz
- Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, 20089 Milan, Italy; (F.F.); (M.S.); (A.C.)
| | - Noemi Rossi
- MOX Laboratory, Department of Mathematics, Politecnico di Milano, 20133 Milan, Italy; (N.R.); (F.I.)
| | - Serena Langella
- Department of Digestive and Hepatobiliary Surgery, Mauriziano Umberto I Hospital, 10128 Turin, Italy; (S.L.); (N.R.); (A.F.)
| | - Andrea Ruzzenente
- Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, University Hospital G.B. Rossi, 37134 Verona, Italy; (A.R.); (M.D.B.); (A.G.)
| | - Matteo Serenari
- General Surgery and Transplant Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy; (M.S.); (M.R.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; (A.C.); (G.E.)
| | - Francesco Ardito
- Hepatobiliary Surgery Unit, A. Gemelli Hospital, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (F.A.); (C.M.); (F.G.)
| | - Alessandro Cucchetti
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; (A.C.); (G.E.)
- Department of General Surgery, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy;
| | - Teresa Gallo
- Department of Radiology, Mauriziano Umberto I Hospital, 10128 Turin, Italy; (T.G.); (S.C.)
| | - Giulia Zamboni
- Department of Radiology, University of Verona, University Hospital G.B. Rossi, 37134 Verona, Italy; (G.Z.); (M.B.)
| | - Cristina Mosconi
- Department of Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy; (C.M.); (G.V.)
| | - Luca Boldrini
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, Italy;
| | - Mariateresa Mirarchi
- Department of General Surgery, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy;
| | - Stefano Cirillo
- Department of Radiology, Mauriziano Umberto I Hospital, 10128 Turin, Italy; (T.G.); (S.C.)
| | - Mario De Bellis
- Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, University Hospital G.B. Rossi, 37134 Verona, Italy; (A.R.); (M.D.B.); (A.G.)
| | - Ilaria Pecorella
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (I.P.); (G.T.)
| | - Nadia Russolillo
- Department of Digestive and Hepatobiliary Surgery, Mauriziano Umberto I Hospital, 10128 Turin, Italy; (S.L.); (N.R.); (A.F.)
| | - Martina Borzi
- Department of Radiology, University of Verona, University Hospital G.B. Rossi, 37134 Verona, Italy; (G.Z.); (M.B.)
| | - Giulio Vara
- Department of Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy; (C.M.); (G.V.)
| | - Caterina Mele
- Hepatobiliary Surgery Unit, A. Gemelli Hospital, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (F.A.); (C.M.); (F.G.)
| | - Giorgio Ercolani
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; (A.C.); (G.E.)
- Department of General Surgery, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy;
| | - Felice Giuliante
- Hepatobiliary Surgery Unit, A. Gemelli Hospital, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; (F.A.); (C.M.); (F.G.)
| | - Matteo Ravaioli
- General Surgery and Transplant Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Sant’Orsola-Malpighi Hospital, 40138 Bologna, Italy; (M.S.); (M.R.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; (A.C.); (G.E.)
| | - Alfredo Guglielmi
- Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, University Hospital G.B. Rossi, 37134 Verona, Italy; (A.R.); (M.D.B.); (A.G.)
| | - Alessandro Ferrero
- Department of Digestive and Hepatobiliary Surgery, Mauriziano Umberto I Hospital, 10128 Turin, Italy; (S.L.); (N.R.); (A.F.)
| | - Martina Sollini
- Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, 20089 Milan, Italy; (F.F.); (M.S.); (A.C.)
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (I.P.); (G.T.)
| | - Arturo Chiti
- Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, 20089 Milan, Italy; (F.F.); (M.S.); (A.C.)
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (I.P.); (G.T.)
| | - Guido Torzilli
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (I.P.); (G.T.)
- Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
| | - Francesca Ieva
- MOX Laboratory, Department of Mathematics, Politecnico di Milano, 20133 Milan, Italy; (N.R.); (F.I.)
- CHDS—Center for Health Data Science, Human Technopole, 20157 Milan, Italy
| | - Luca Viganò
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (I.P.); (G.T.)
- Hepatobiliary Unit, Department of Minimally Invasive General & Oncologic Surgery, Humanitas Gavazzeni University Hospital, 24125 Bergamo, Italy
| |
Collapse
|
13
|
Han Z, Dai H, Chen X, Gao L, Chen X, Yan C, Ye R, Li Y. Delta-radiomics models based on multi-phase contrast-enhanced magnetic resonance imaging can preoperatively predict glypican-3-positive hepatocellular carcinoma. Front Physiol 2023; 14:1138239. [PMID: 37601639 PMCID: PMC10435992 DOI: 10.3389/fphys.2023.1138239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 07/14/2023] [Indexed: 08/22/2023] Open
Abstract
Objectives: The aim of this study is to investigate the value of multi-phase contrast-enhanced magnetic resonance imaging (CE-MRI) based on the delta radiomics model for identifying glypican-3 (GPC3)-positive hepatocellular carcinoma (HCC). Methods: One hundred and twenty-six patients with pathologically confirmed HCC (training cohort: n = 88 and validation cohort: n = 38) were retrospectively recruited. Basic information was obtained from medical records. Preoperative multi-phase CE-MRI images were reviewed, and the 3D volumes of interest (VOIs) of the whole tumor were delineated on non-contrast T1-weighted imaging (T1), arterial phase (AP), portal venous phase (PVP), delayed phase (DP), and hepatobiliary phase (HBP). One hundred and seven original radiomics features were extracted from each phase, and delta-radiomics features were calculated. After a two-step feature selection strategy, radiomics models were built using two classification algorithms. A nomogram was constructed by combining the best radiomics model and clinical risk factors. Results: Serum alpha-fetoprotein (AFP) (p = 0.013) was significantly related to GPC3-positive HCC. The optimal radiomics model is composed of eight delta-radiomics features with the AUC of 0.805 and 0.857 in the training and validation cohorts, respectively. The nomogram integrated the radiomics score, and AFP performed excellently (training cohort: AUC = 0.844 and validation cohort: AUC = 0.862). The calibration curve showed good agreement between the nomogram-predicted probabilities and GPC3 actual expression in both training and validation cohorts. Decision curve analysis further demonstrates the clinical practicality of the nomogram. Conclusion: Multi-phase CE-MRI based on the delta-radiomics model can non-invasively predict GPC3-positive HCC and can be a useful method for individualized diagnosis and treatment.
Collapse
Affiliation(s)
- Zewen Han
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- School of Medical Imaging, Fujian Medical University, Fuzhou, China
| | - Hanting Dai
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- School of Medical Imaging, Fujian Medical University, Fuzhou, China
| | - Xiaolin Chen
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
| | - Lanmei Gao
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
| | - Xiaojie Chen
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
| | - Chuan Yan
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
| | - Rongping Ye
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
| | - Yueming Li
- Department of Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- Key Laboratory of Radiation Biology (Fujian Medical University), Fujian Province University, Fuzhou, Fujian, China
| |
Collapse
|
14
|
Cerrito L, Ainora ME, Borriello R, Piccirilli G, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives. Cancers (Basel) 2023; 15:3393. [PMID: 37444503 DOI: 10.3390/cancers15133393] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Revised: 06/23/2023] [Accepted: 06/25/2023] [Indexed: 07/15/2023] Open
Abstract
Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA's poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA's most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications.
Collapse
Affiliation(s)
- Lucia Cerrito
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Maria Elena Ainora
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Raffaele Borriello
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Giulia Piccirilli
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Matteo Garcovich
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Laura Riccardi
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Maurizio Pompili
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Antonio Gasbarrini
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Maria Assunta Zocco
- CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| |
Collapse
|
15
|
Le VH, Kha QH, Minh TNT, Nguyen VH, Le VL, Le NQK. Development and Validation of CT-Based Radiomics Signature for Overall Survival Prediction in Multi-organ Cancer. J Digit Imaging 2023; 36:911-922. [PMID: 36717518 PMCID: PMC10287593 DOI: 10.1007/s10278-023-00778-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 01/11/2023] [Accepted: 01/12/2023] [Indexed: 02/01/2023] Open
Abstract
The malignant tumors in nature share some common morphological characteristics. Radiomics is not only images but also data; we think that a probability exists in a set of radiomics signatures extracted from CT scan images of one cancer tumor in one specific organ also be utilized for overall survival prediction in different types of cancers in different organs. The retrospective study enrolled four data sets of cancer patients in three different organs (420, 157, 137, and 191 patients for lung 1 training, lung 2 testing, and two external validation set: kidney and head and neck, respectively). In the training set, radiomics features were obtained from CT scan images, and essential features were chosen by LASSO algorithm. Univariable and multivariable analyses were then conducted to find a radiomics signature via Cox proportional hazard regression. The Kaplan-Meier curve was performed based on the risk score. The integrated time-dependent area under the ROC curve (iAUC) was calculated for each predictive model. In the training set, Kaplan-Meier curve classified patients as high or low-risk groups (p-value < 0.001; log-rank test). The risk score of radiomics signature was locked and independently evaluated in the testing set, and two external validation sets showed significant differences (p-value < 0.05; log-rank test). A combined model (radiomics + clinical) showed improved iAUC in lung 1, lung 2, head and neck, and kidney data set are 0.621 (95% CI 0.588, 0.654), 0.736 (95% CI 0.654, 0.819), 0.732 (95% CI 0.655, 0.809), and 0.834 (95% CI 0.722, 0.946), respectively. We believe that CT-based radiomics signatures for predicting overall survival in various cancer sites may exist.
Collapse
Affiliation(s)
- Viet Huan Le
- International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan
- Department of Thoracic Surgery, Khanh Hoa General Hospital, Nha Trang, 65000, Vietnam
| | - Quang Hien Kha
- International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan
| | - Tran Nguyen Tuan Minh
- International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan
| | - Van Hiep Nguyen
- International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan
- Oncology Center, Bai Chay Hospital, Quang Ninh, 20000, Vietnam
| | - Van Long Le
- International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan
- Department of Anesthesiology and Critical Care, Hue University of Medicine and Pharmacy, Hue University, Hue City, 52000, Vietnam
| | - Nguyen Quoc Khanh Le
- Professional Master Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University, Taipei, 106, Taiwan.
- Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei, 106, Taiwan.
- Translational Imaging Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan.
| |
Collapse
|
16
|
Zhang YP, Zhang XY, Cheng YT, Li B, Teng XZ, Zhang J, Lam S, Zhou T, Ma ZR, Sheng JB, Tam VCW, Lee SWY, Ge H, Cai J. Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling. Mil Med Res 2023; 10:22. [PMID: 37189155 DOI: 10.1186/s40779-023-00458-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Accepted: 05/04/2023] [Indexed: 05/17/2023] Open
Abstract
Modern medicine is reliant on various medical imaging technologies for non-invasively observing patients' anatomy. However, the interpretation of medical images can be highly subjective and dependent on the expertise of clinicians. Moreover, some potentially useful quantitative information in medical images, especially that which is not visible to the naked eye, is often ignored during clinical practice. In contrast, radiomics performs high-throughput feature extraction from medical images, which enables quantitative analysis of medical images and prediction of various clinical endpoints. Studies have reported that radiomics exhibits promising performance in diagnosis and predicting treatment responses and prognosis, demonstrating its potential to be a non-invasive auxiliary tool for personalized medicine. However, radiomics remains in a developmental phase as numerous technical challenges have yet to be solved, especially in feature engineering and statistical modeling. In this review, we introduce the current utility of radiomics by summarizing research on its application in the diagnosis, prognosis, and prediction of treatment responses in patients with cancer. We focus on machine learning approaches, for feature extraction and selection during feature engineering and for imbalanced datasets and multi-modality fusion during statistical modeling. Furthermore, we introduce the stability, reproducibility, and interpretability of features, and the generalizability and interpretability of models. Finally, we offer possible solutions to current challenges in radiomics research.
Collapse
Affiliation(s)
- Yuan-Peng Zhang
- Department of Medical Informatics, Nantong University, Nantong, 226001, Jiangsu, China
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
- The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, 518000, Guangdong, China
| | - Xin-Yun Zhang
- Department of Medical Informatics, Nantong University, Nantong, 226001, Jiangsu, China
| | - Yu-Ting Cheng
- Department of Medical Informatics, Nantong University, Nantong, 226001, Jiangsu, China
| | - Bing Li
- Department of Radiation Oncology, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, Henan, China
| | - Xin-Zhi Teng
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Jiang Zhang
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Saikit Lam
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Ta Zhou
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Zong-Rui Ma
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Jia-Bao Sheng
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Victor C W Tam
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Shara W Y Lee
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China
| | - Hong Ge
- Department of Radiation Oncology, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, Henan, China
| | - Jing Cai
- Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hong Kong, 999077, China.
- The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, 518000, Guangdong, China.
| |
Collapse
|
17
|
Zhong JG, Shi L, Liu J, Cao F, Ma YQ, Zhang Y. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance. Sci Rep 2023; 13:4846. [PMID: 36964192 PMCID: PMC10038986 DOI: 10.1038/s41598-023-31869-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 03/20/2023] [Indexed: 03/26/2023] Open
Abstract
To develop MRI-based radiomics model for predicting prostate cancer (PCa) in men with prostate-specific antigen (PSA) levels of 4-10 ng/mL, to compare the performance of radiomics model and PI-RADS v2.1, and to further verify the predictive ability of radiomics model for lesions with different PI-RADS v2.1 score. 171 patients with PSA levels of 4-10 ng/mL were divided into training (n = 119) and testing (n = 52) groups. PI-RADS v2.1 score was assessed by two radiologists. All volumes of interest were segmented on T2-weighted imaging, diffusion weighted imaging, and apparent diffusion coefficient sequences, from which quantitative radiomics features were extracted. Multivariate logistic regression analysis was performed to establish radiomics model for predicting PCa. The diagnostic performance was assessed using receiver operating characteristic curve analysis. The radiomics model exhibited the best performance in predicting PCa, which was better than the performance of PI-RADS v2.1 scoring by the junior radiologist in the training group [area under the curve (AUC): 0.932 vs 0.803], testing group (AUC: 0.922 vs 0.797), and the entire cohort (AUC: 0.927 vs 0.801) (P < 0.05). The radiomics model performed well for lesions with PI-RADS v2.1 score of 3 (AUC = 0.854, sensitivity = 84.62%, specificity = 84.34%) and PI-RADS v2.1 score of 4-5 (AUC = 0.967, sensitivity = 98.11%, specificity = 86.36%) assigned by junior radiologist. The radiomics model quantitatively outperformed PI-RADS v2.1 for noninvasive prediction of PCa in men with PSA levels of 4-10 ng/mL. The model can help improve the diagnostic performance of junior radiologists and facilitate better decision-making by urologists for management of lesions with different PI-RADS v2.1 score.
Collapse
Affiliation(s)
- Jian-Guo Zhong
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
| | - Lin Shi
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
| | - Jing Liu
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
| | - Fang Cao
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
| | - Yan-Qing Ma
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
| | - Yang Zhang
- Cancer Center, Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
| |
Collapse
|
18
|
Liufu Y, Wen Y, Wu W, Su R, Liu S, Li J, Pan X, Chen K, Guan Y. Radiomics Analysis of Multiphasic Computed Tomography Images for Distinguishing High-Risk Thymic Epithelial Tumors From Low-Risk Thymic Epithelial Tumors. J Comput Assist Tomogr 2023; 47:220-228. [PMID: 36877755 DOI: 10.1097/rct.0000000000001407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
Abstract
OBJECTIVES The objective of this study is to preoperatively investigate the value of multiphasic contrast-enhanced computed tomography (CT)-based radiomics signatures for distinguishing high-risk thymic epithelial tumors (HTET) from low-risk thymic epithelial tumors (LTET) compared with conventional CT signatures. MATERIALS AND METHODS Pathologically confirmed 305 thymic epithelial tumors (TETs), including 147 LTET (Type A/AB/B1) and 158 HTET (Type B2/B3/C), were retrospectively analyzed, and were randomly divided into training (n = 214) and validation cohorts (n = 91). All patients underwent nonenhanced, arterial contrast-enhanced, and venous contrast-enhanced CT analysis. The least absolute shrinkage and selection operator regression with 10-fold cross-validation was performed for radiomic models building, and multivariate logistic regression analysis was performed for radiological and combined models building. The performance of the model was evaluated by the area under the receiver operating characteristic curve (AUC of ROC), and the AUCs were compared using the Delong test. Decision curve analysis was used to evaluate the clinical value of each model. Nomogram and calibration curves were plotted for the combined model. RESULTS The AUCs for radiological model in the training and validation cohorts were 0.756 and 0.733, respectively. For nonenhanced, arterial contrast-enhanced, venous contrast-enhanced CT and 3-phase images combined radiomics models, the AUCs were 0.940, 0.946, 0.960, and 0.986, respectively, in the training cohort, whereas 0.859, 0.876, 0.930, and 0.923, respectively, in the validation cohort. The combined model, including CT morphology and radiomics signature, showed AUCs of 0.990 and 0.943 in the training and validation cohorts, respectively. Delong test and decision curve analysis showed that the predictive performance and clinical value of the 4 radiomics models and combined model were greater than the radiological model ( P < 0.05). CONCLUSIONS The combined model, including CT morphology and radiomics signature, greatly improved the predictive performance for distinguishing HTET from LTET. Radiomics texture analysis can be used as a noninvasive method for preoperative prediction of the pathological subtypes of TET.
Collapse
Affiliation(s)
- Yuling Liufu
- From the Department of Radiology, The Fifth Affiliated Hospital of Guangzhou Medical University
| | - Yanhua Wen
- From the Department of Radiology, The Fifth Affiliated Hospital of Guangzhou Medical University
| | - Wensheng Wu
- From the Department of Radiology, The Fifth Affiliated Hospital of Guangzhou Medical University
| | - Ruihua Su
- From the Department of Radiology, The Fifth Affiliated Hospital of Guangzhou Medical University
| | - Shuya Liu
- From the Department of Radiology, The Fifth Affiliated Hospital of Guangzhou Medical University
| | - Jingxu Li
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University
| | - Xiaohuan Pan
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University
| | - Kai Chen
- Department of Radiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Yubao Guan
- From the Department of Radiology, The Fifth Affiliated Hospital of Guangzhou Medical University
| |
Collapse
|
19
|
White LM, Atinga A, Naraghi AM, Lajkosz K, Wunder JS, Ferguson P, Tsoi K, Griffin A, Haider M. T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival. Skeletal Radiol 2023; 52:553-564. [PMID: 35778618 DOI: 10.1007/s00256-022-04098-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 06/16/2022] [Accepted: 06/17/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To analyze radiomic features obtained from pre-treatment T2-weighted MRI acquisitions in patients with histologically proven intramedullary high-grade osteosarcomas and assess the accuracy of radiomic modelling as predictive biomarker of tumor necrosis following neoadjuvant chemotherapy (NAC), overall survival (OS), and disease-free survival (DFS). MATERIALS AND METHODS Pre-treatment MRI exams in 105 consecutive patients who underwent NAC and resection of high-grade intramedullary osteosarcoma were evaluated. Histologic necrosis following NAC, and clinical outcome-survival data was collected for each case. Radiomic features were extracted from segmentations performed by two readers, with poorly reproducible features excluded from further analysis. Cox proportional hazard model and Spearman correlation with multivariable modelling were used for assessing relationships of radiomics features with OS, DFS, and histologic tumor necrosis. RESULTS Study included 74 males, 31 females (mean 32.5yrs, range 15-77 years). Histologic assessment of tumor necrosis following NAC was available in 104 cases, with good response (≥ 90% necrosis) in 41, and poor response in 63. Fifty-three of 105 patients were alive at follow-up (median 40 months, range: 2-213 months). Median OS was 89 months. Excluding 14 patients with metastases at presentation, median DFS was 19 months. Eleven radiomics features were employed in final radiomics model predicting histologic tumor necrosis (mean AUC 0.708 ± 0.046). Thirteen radiomic features were used in model predicting OS (mean concordance index 0.741 ± 0.011), and 12 features retained in predicting DFS (mean concordance index 0.745 ± 0.010). CONCLUSIONS T2-weighted MRI radiomic models demonstrate promising results as potential prognostic biomarkers of prospective tumor response to neoadjuvant chemotherapy and prediction of clinical outcomes in conventional osteosarcoma.
Collapse
Affiliation(s)
- Lawrence M White
- Department of Medical Imaging, University of Toronto, Toronto, ON, Canada. .,Joint Department of Medical Imaging, Mount Sinai Hospital, University Health Network and Women's College Hospital, Rm 562-A, 600 University Ave, Toronto, ON, M5G 1X5, Canada. .,Toronto Sarcoma Program, Mount Sinai Hospital, Toronto, ON, Canada.
| | - Angela Atinga
- Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.,Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Ali M Naraghi
- Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.,Joint Department of Medical Imaging, Mount Sinai Hospital, University Health Network and Women's College Hospital, Rm 562-A, 600 University Ave, Toronto, ON, M5G 1X5, Canada.,Toronto Sarcoma Program, Mount Sinai Hospital, Toronto, ON, Canada
| | - Katherine Lajkosz
- Department of Biostatistics, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Jay S Wunder
- Toronto Sarcoma Program, Mount Sinai Hospital, Toronto, ON, Canada.,Department of Surgery, Division of Orthopedic Surgery, Musculoskeletal Oncology, Mount Sinai Hospital, Toronto, ON, Canada
| | - Peter Ferguson
- Toronto Sarcoma Program, Mount Sinai Hospital, Toronto, ON, Canada.,Department of Surgery, Division of Orthopedic Surgery, Musculoskeletal Oncology, Mount Sinai Hospital, Toronto, ON, Canada
| | - Kim Tsoi
- Toronto Sarcoma Program, Mount Sinai Hospital, Toronto, ON, Canada.,Department of Surgery, Division of Orthopedic Surgery, Musculoskeletal Oncology, Mount Sinai Hospital, Toronto, ON, Canada
| | - Anthony Griffin
- Department of Surgery, Division of Orthopedic Surgery, Musculoskeletal Oncology, Mount Sinai Hospital, Toronto, ON, Canada
| | - Masoom Haider
- Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.,Joint Department of Medical Imaging, Mount Sinai Hospital, University Health Network and Women's College Hospital, Rm 562-A, 600 University Ave, Toronto, ON, M5G 1X5, Canada
| |
Collapse
|
20
|
Chen P, Yang Z, Zhang H, Huang G, Li Q, Ning P, Yu H. Personalized intrahepatic cholangiocarcinoma prognosis prediction using radiomics: Application and development trend. Front Oncol 2023; 13:1133867. [PMID: 37035147 PMCID: PMC10076873 DOI: 10.3389/fonc.2023.1133867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Accepted: 03/13/2023] [Indexed: 04/11/2023] Open
Abstract
Radiomics was proposed by Lambin et al. in 2012 and since then there has been an explosion of related research. There has been significant interest in developing high-throughput methods that can automatically extract a large number of quantitative image features from medical images for better diagnostic or predictive performance. There have also been numerous radiomics investigations on intrahepatic cholangiocarcinoma in recent years, but no pertinent review materials are readily available. This work discusses the modeling analysis of radiomics for the prediction of lymph node metastasis, microvascular invasion, and early recurrence of intrahepatic cholangiocarcinoma, as well as the use of deep learning. This paper briefly reviews the current status of radiomics research to provide a reference for future studies.
Collapse
Affiliation(s)
- Pengyu Chen
- Department of Hepatobiliary Surgery, Henan University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
| | - Zhenwei Yang
- Department of Hepatobiliary Surgery, Henan University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
| | - Haofeng Zhang
- Department of Hepatobiliary Surgery, People’s Hospital of Zhengzhou University, Zhengzhou, China
| | - Guan Huang
- Department of Hepatobiliary Surgery, People’s Hospital of Zhengzhou University, Zhengzhou, China
| | - Qingshan Li
- Department of Hepatobiliary Surgery, Henan Provincial People’s Hospital, Zhengzhou, China
| | - Peigang Ning
- Department of Radiology, People’s Hospital of Zhengzhou University, Zhengzhou, China
| | - Haibo Yu
- Department of Hepatobiliary Surgery, Henan University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Department of Hepatobiliary Surgery, People’s Hospital of Zhengzhou University, Zhengzhou, China
- Department of Hepatobiliary Surgery, Henan Provincial People’s Hospital, Zhengzhou, China
- *Correspondence: Haibo Yu,
| |
Collapse
|
21
|
Nie T, Liu D, Ai S, He Y, Yang M, Chen J, Yuan Z, Liu Y. A radiomics nomogram analysis based on CT images and clinical features for preoperative Lauren classification in gastric cancer. Jpn J Radiol 2022; 41:401-408. [PMID: 36370327 DOI: 10.1007/s11604-022-01360-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Accepted: 11/01/2022] [Indexed: 11/14/2022]
Abstract
PURPOSE To develop a combined radiomics nomogram based on computed tomography (CT) images and clinical features to preoperatively distinguish Lauren's diffuse-type gastric cancer (GC) from intestinal-type GC. METHODS Ninety-five patients with Lauren's intestinal or diffuse-type GC confirmed by postoperative pathology had their preoperative clinical information and dynamic contrast CT images retrospectively analyzed and were subdivided into training and test groups in a 7:3 ratio. To select the optimal features and construct the radiomic signatures, we extracted, filtered, and minimized the radiomic features from arterial phase (AP) and venous phase (VP) CT images. We constructed four models (clinical model, AP radiomics model, VP radiomics model, and radiomics-clinical model) to assess and compare their predictive performance between the intestinal- and diffuse-type GC. Receiver-operating characteristic (ROC) curve, area under the ROC curve (AUC), and the DeLong test were used for assessment and comparison. In this study, radiomic nomograms integrating combined radiomic signatures and clinical characteristics were developed. RESULTS Compared to the AP radiomics model, the VP radiomics model had better performance, with an AUC of 0.832 (95% confidence interval [CI], 0.735, 0.929) in the training cohort and 0.760 (95% CI 0.580, 0.940) in the test cohort. Among the combined models that assessed Lauren's type GC, the model including age and VP radiomics showed the best performance, with an AUC of 0.849 (95% CI 0.758, 0.940) in the training cohort and 0.793 (95% CI 0.629, 0.957) in the test cohort. CONCLUSIONS Nomogram incorporating radiomic signatures and clinical features effectively differentiated Lauren's diffuse-type from intestinal-type GC.
Collapse
Affiliation(s)
- Tingting Nie
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China
| | - Dan Liu
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China
| | - Shuangquan Ai
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China
| | - Yaoyao He
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China
| | - Miao Yang
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China
| | - Jun Chen
- GE Healthiness, Shanghai, 200126, People's Republic of China
| | - Zilong Yuan
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China.
| | - Yulin Liu
- Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Load, Hongshan District, Wuhan, 430079, Hubei, People's Republic of China.
| |
Collapse
|
22
|
Computed tomography-based radiomics nomogram for the preoperative prediction of perineural invasion in colorectal cancer: a multicentre study. ABDOMINAL RADIOLOGY (NEW YORK) 2022; 47:3251-3263. [PMID: 35960308 DOI: 10.1007/s00261-022-03620-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 07/10/2022] [Accepted: 07/11/2022] [Indexed: 01/18/2023]
Abstract
PURPOSE To develop and validate a computed tomography (CT) radiomics nomogram from multicentre datasets for preoperative prediction of perineural invasion (PNI) in colorectal cancer. METHODS A total of 299 patients with histologically confirmed colorectal cancer from three hospitals were enrolled in this retrospective study. Radiomic features were extracted from the whole tumour volume. The least absolute shrinkage and selection operator logistic regression was applied for feature selection and radiomics signature construction. Finally, a radiomics nomogram combining the radiomics score and clinical predictors was established. The receiver operating characteristic curve and decision curve analysis (DCA) were used to evaluate the predictive performance of the radiomics nomogram in the training cohort, internal validation and external validation cohorts. RESULTS Twelve radiomics features extracted from the whole tumour volume were used to construct the radiomics model. The area under the curve (AUC) values of the radiomics model in the training cohort, internal validation cohort, external validation cohort 1, and external validation cohort 2 were 0.82 (0.75-0.90), 0.77 (0.62-0.92), 0.71 (0.56-0.85), and 0.73 (0.60-0.85), respectively. The nomogram, which combined the radiomics score with T category and N category by CT, yielded better performance in the training cohort (AUC = 0.88), internal validation cohort (AUC = 0.80), external validation cohort 1 (AUC = 0.75), and external validation cohort 2 (AUC = 0.76). DCA confirmed the clinical utility of the nomogram. CONCLUSIONS The CT-based radiomics nomogram has the potential to accurately predict PNI in patients with colorectal cancer.
Collapse
|
23
|
Du KP, Huang WP, Liu SY, Chen YJ, Li LM, Liu XN, Han YJ, Zhou Y, Liu CC, Gao JB. Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction. World J Gastroenterol 2022; 28:4363-4375. [PMID: 36159013 PMCID: PMC9453771 DOI: 10.3748/wjg.v28.i31.4363] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 06/11/2022] [Accepted: 07/25/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The biological behavior of carcinoma of the esophagogastric junction (CEGJ) is different from that of gastric or esophageal cancer. Differentiating squamous cell carcinoma of the esophagogastric junction (SCCEG) from adenocarcinoma of the esophagogastric junction (AEG) can indicate Siewert stage and whether the surgical route for patients with CEGJ is transthoracic or transabdominal, as well as aid in determining the extent of lymph node dissection. With the development of neoadjuvant therapy, preoperative determination of pathological type can help in the selection of neoadjuvant radiotherapy and chemotherapy regimens.
AIM To establish and evaluate computed tomography (CT)-based multiscale and multiphase radiomics models to distinguish SCCEG and AEG preoperatively.
METHODS We retrospectively analyzed the preoperative contrasted-enhanced CT imaging data of single-center patients with pathologically confirmed SCCEG (n = 130) and AEG (n = 130). The data were divided into either a training (n = 182) or a test group (n = 78) at a ratio of 7:3. A total of 1409 radiomics features were separately extracted from two dimensional (2D) or three dimensional (3D) regions of interest in arterial and venous phases. Intra-/inter-observer consistency analysis, correlation analysis, univariate analysis, least absolute shrinkage and selection operator regression, and backward stepwise logical regression were applied for feature selection. Totally, six logistic regression models were established based on 2D and 3D multi-phase features. The receiver operating characteristic curve analysis, the continuous net reclassification improvement (NRI), and the integrated discrimination improvement (IDI) were used for assessing model discrimination performance. Calibration and decision curves were used to assess the calibration and clinical usefulness of the model, respectively.
RESULTS The 2D-venous model (5 features, AUC: 0.849) performed better than 2D-arterial (5 features, AUC: 0.808). The 2D-arterial-venous combined model could further enhance the performance (AUC: 0.869). The 3D-venous model (7 features, AUC: 0.877) performed better than 3D-arterial (10 features, AUC: 0.876). And the 3D-arterial-venous combined model (AUC: 0.904) outperformed other single-phase-based models. The venous model showed a positive improvement compared with the arterial model (NRI > 0, IDI > 0), and the 3D-venous and combined models showed a significant positive improvement compared with the 2D-venous and combined models (P < 0.05). Decision curve analysis showed that combined 3D-arterial-venous model and 3D-venous model had a higher net clinical benefit within the same threshold probability range in the test group.
CONCLUSION The combined arterial-venous CT radiomics model based on 3D segmentation can improve the performance in differentiating EGJ squamous cell carcinoma from adenocarcinoma.
Collapse
Affiliation(s)
- Ke-Pu Du
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Wen-Peng Huang
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Si-Yun Liu
- Department of Pharmaceutical Diagnostics, General Electric Company Healthcare, Beijing 100176, China
| | - Yun-Jin Chen
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Li-Ming Li
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Xiao-Nan Liu
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Yi-Jing Han
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Yue Zhou
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Chen-Chen Liu
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| | - Jian-Bo Gao
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
| |
Collapse
|
24
|
Zhong J, Hu Y, Zhang G, Xing Y, Ding D, Ge X, Pan Z, Yang Q, Yin Q, Zhang H, Zhang H, Yao W. An updated systematic review of radiomics in osteosarcoma: utilizing CLAIM to adapt the increasing trend of deep learning application in radiomics. Insights Imaging 2022; 13:138. [PMID: 35986808 PMCID: PMC9392674 DOI: 10.1186/s13244-022-01277-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Accepted: 07/24/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Objective
To update the systematic review of radiomics in osteosarcoma.
Methods
PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang Data were searched to identify articles on osteosarcoma radiomics until May 15, 2022. The studies were assessed by Radiomics Quality Score (RQS), Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement, Checklist for Artificial Intelligence in Medical Imaging (CLAIM), and modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The evidence supporting radiomics application for osteosarcoma was rated according to meta-analysis results.
Results
Twenty-nine articles were included. The average of the ideal percentage of RQS, the TRIPOD adherence rate and the CLAIM adherence rate were 29.2%, 59.2%, and 63.7%, respectively. RQS identified a radiomics-specific issue of phantom study. TRIPOD addressed deficiency in blindness of assessment. CLAIM and TRIPOD both pointed out shortness in missing data handling and sample size or power calculation. CLAIM identified extra disadvantages in data de-identification and failure analysis. External validation and open science were emphasized by all the above three tools. The risk of bias and applicability concerns were mainly related to the index test. The meta-analysis of radiomics predicting neoadjuvant chemotherapy response by MRI presented a diagnostic odds ratio (95% confidence interval) of 28.83 (10.27–80.95) on testing datasets and was rated as weak evidence.
Conclusions
The quality of osteosarcoma radiomics studies is insufficient. More investigation is needed before using radiomics to optimize osteosarcoma treatment. CLAIM is recommended to guide the design and reporting of radiomics research.
Collapse
|
25
|
Performance of CT radiomics in predicting the overall survival of patients with stage III clear cell renal carcinoma after radical nephrectomy. Radiol Med 2022; 127:837-847. [DOI: 10.1007/s11547-022-01526-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 07/04/2022] [Indexed: 10/17/2022]
|
26
|
Staal FCR, Aalbersberg EA, van der Velden D, Wilthagen EA, Tesselaar MET, Beets-Tan RGH, Maas M. GEP-NET radiomics: a systematic review and radiomics quality score assessment. Eur Radiol 2022; 32:7278-7294. [PMID: 35882634 DOI: 10.1007/s00330-022-08996-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 05/25/2022] [Accepted: 06/26/2022] [Indexed: 11/04/2022]
Abstract
OBJECTIVE The number of radiomics studies in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is rapidly increasing. This systematic review aims to provide an overview of the available evidence of radiomics for clinical outcome measures in GEP-NETs, to understand which applications hold the most promise and which areas lack evidence. METHODS PubMed, Embase, and Wiley/Cochrane Library databases were searched and a forward and backward reference check of the identified studies was executed. Inclusion criteria were (1) patients with GEP-NETs and (2) radiomics analysis on CT, MRI or PET. Two reviewers independently agreed on eligibility and assessed methodological quality with the radiomics quality score (RQS) and extracted outcome data. RESULTS In total, 1364 unique studies were identified and 45 were included for analysis. Most studies focused on GEP-NET grade and differential diagnosis of GEP-NETs from other neoplasms, while only a minority analysed treatment response or long-term outcomes. Several studies were able to predict tumour grade or to differentiate GEP-NETs from other lesions with a good performance (AUCs 0.74-0.96 and AUCs 0.80-0.99, respectively). Only one study developed a model to predict recurrence in pancreas NETs (AUC 0.77). The included studies reached a mean RQS of 18%. CONCLUSION Although radiomics for GEP-NETs is still a relatively new area, some promising models have been developed. Future research should focus on developing robust models for clinically relevant aims such as prediction of response or long-term outcome in GEP-NET, since evidence for these aims is still scarce. KEY POINTS • The majority of radiomics studies in gastroenteropancreatic neuroendocrine tumours is of low quality. • Most evidence for radiomics is available for the identification of tumour grade or differentiation of gastroenteropancreatic neuroendocrine tumours from other neoplasms. • Radiomics for the prediction of response or long-term outcome in gastroenteropancreatic neuroendocrine tumours warrants further research.
Collapse
Affiliation(s)
- Femke C R Staal
- Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.,GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.,The Netherlands Cancer Institute/University Medical Center Utrecht Center for Neuroendocrine Tumors, ENETS Center of Excellence, Amsterdam/Utrecht, The Netherlands
| | - Else A Aalbersberg
- The Netherlands Cancer Institute/University Medical Center Utrecht Center for Neuroendocrine Tumors, ENETS Center of Excellence, Amsterdam/Utrecht, The Netherlands.,Department of Nuclear Medicine, The Netherlands Cancer Institute Amsterdam, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
| | - Daphne van der Velden
- Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
| | - Erica A Wilthagen
- Scientific Information Service, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
| | - Margot E T Tesselaar
- The Netherlands Cancer Institute/University Medical Center Utrecht Center for Neuroendocrine Tumors, ENETS Center of Excellence, Amsterdam/Utrecht, The Netherlands.,Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
| | - Regina G H Beets-Tan
- Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.,GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.,Faculty of Health Sciences, University of Southern Denmark, J. B. Winsløws Vej 19, 3, 5000, Odense, Denmark
| | - Monique Maas
- Department of Radiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
| |
Collapse
|
27
|
Fiz F, Jayakody Arachchige VS, Gionso M, Pecorella I, Selvam A, Wheeler DR, Sollini M, Viganò L. Radiomics of Biliary Tumors: A Systematic Review of Current Evidence. Diagnostics (Basel) 2022; 12:diagnostics12040826. [PMID: 35453878 PMCID: PMC9024804 DOI: 10.3390/diagnostics12040826] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2022] [Revised: 03/19/2022] [Accepted: 03/25/2022] [Indexed: 02/06/2023] Open
Abstract
Biliary tumors are rare diseases with major clinical unmet needs. Standard imaging modalities provide neither a conclusive diagnosis nor robust biomarkers to drive treatment planning. In several neoplasms, texture analyses non-invasively unveiled tumor characteristics and aggressiveness. The present manuscript aims to summarize the available evidence about the role of radiomics in the management of biliary tumors. A systematic review was carried out through the most relevant databases. Original, English-language articles published before May 2021 were considered. Three main outcome measures were evaluated: prediction of pathology data; prediction of survival; and differential diagnosis. Twenty-seven studies, including a total of 3605 subjects, were identified. Mass-forming intrahepatic cholangiocarcinoma (ICC) was the subject of most studies (n = 21). Radiomics reliably predicted lymph node metastases (range, AUC = 0.729−0.900, accuracy = 0.69−0.83), tumor grading (AUC = 0.680−0.890, accuracy = 0.70−0.82), and survival (C-index = 0.673−0.889). Textural features allowed for the accurate differentiation of ICC from HCC, mixed HCC-ICC, and inflammatory masses (AUC > 0.800). For all endpoints (pathology/survival/diagnosis), the predictive/prognostic models combining radiomic and clinical data outperformed the standard clinical models. Some limitations must be acknowledged: all studies are retrospective; the analyzed imaging modalities and phases are heterogeneous; the adoption of signatures/scores limits the interpretability and applicability of results. In conclusion, radiomics may play a relevant role in the management of biliary tumors, from diagnosis to treatment planning. It provides new non-invasive biomarkers, which are complementary to the standard clinical biomarkers; however, further studies are needed for their implementation in clinical practice.
Collapse
Affiliation(s)
- Francesco Fiz
- Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy; (F.F.); (M.S.)
| | - Visala S Jayakody Arachchige
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
| | - Matteo Gionso
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
| | - Ilaria Pecorella
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
| | - Apoorva Selvam
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
| | - Dakota Russell Wheeler
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
| | - Martina Sollini
- Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy; (F.F.); (M.S.)
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
| | - Luca Viganò
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy; (V.S.J.A.); (M.G.); (I.P.); (A.S.); (D.R.W.)
- Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
- Correspondence: ; Tel.: +39-02-8224-7361
| |
Collapse
|
28
|
Wan Q, Zhou J, Xia X, Hu J, Wang P, Peng Y, Zhang T, Sun J, Song Y, Yang G, Li X. Diagnostic Performance of 2D and 3D T2WI-Based Radiomics Features With Machine Learning Algorithms to Distinguish Solid Solitary Pulmonary Lesion. Front Oncol 2021; 11:683587. [PMID: 34868905 PMCID: PMC8637439 DOI: 10.3389/fonc.2021.683587] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Accepted: 10/29/2021] [Indexed: 11/13/2022] Open
Abstract
Objective To evaluate the performance of 2D and 3D radiomics features with different machine learning approaches to classify SPLs based on magnetic resonance(MR) T2 weighted imaging (T2WI). Material and Methods A total of 132 patients with pathologically confirmed SPLs were examined and randomly divided into training (n = 92) and test datasets (n = 40). A total of 1692 3D and 1231 2D radiomics features per patient were extracted. Both radiomics features and clinical data were evaluated. A total of 1260 classification models, comprising 3 normalization methods, 2 dimension reduction algorithms, 3 feature selection methods, and 10 classifiers with 7 different feature numbers (confined to 3–9), were compared. The ten-fold cross-validation on the training dataset was applied to choose the candidate final model. The area under the receiver operating characteristic curve (AUC), precision-recall plot, and Matthews Correlation Coefficient were used to evaluate the performance of machine learning approaches. Results The 3D features were significantly superior to 2D features, showing much more machine learning combinations with AUC greater than 0.7 in both validation and test groups (129 vs. 11). The feature selection method Analysis of Variance(ANOVA), Recursive Feature Elimination(RFE) and the classifier Logistic Regression(LR), Linear Discriminant Analysis(LDA), Support Vector Machine(SVM), Gaussian Process(GP) had relatively better performance. The best performance of 3D radiomics features in the test dataset (AUC = 0.824, AUC-PR = 0.927, MCC = 0.514) was higher than that of 2D features (AUC = 0.740, AUC-PR = 0.846, MCC = 0.404). The joint 3D and 2D features (AUC=0.813, AUC-PR = 0.926, MCC = 0.563) showed similar results as 3D features. Incorporating clinical features with 3D and 2D radiomics features slightly improved the AUC to 0.836 (AUC-PR = 0.918, MCC = 0.620) and 0.780 (AUC-PR = 0.900, MCC = 0.574), respectively. Conclusions After algorithm optimization, 2D feature-based radiomics models yield favorable results in differentiating malignant and benign SPLs, but 3D features are still preferred because of the availability of more machine learning algorithmic combinations with better performance. Feature selection methods ANOVA and RFE, and classifier LR, LDA, SVM and GP are more likely to demonstrate better diagnostic performance for 3D features in the current study.
Collapse
Affiliation(s)
- Qi Wan
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Jiaxuan Zhou
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Xiaoying Xia
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Jianfeng Hu
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Peng Wang
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Yu Peng
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | | | | | - Yang Song
- Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai, China
| | - Guang Yang
- Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai, China
| | - Xinchun Li
- Department of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| |
Collapse
|
29
|
Mingzhu L, Yaqiong G, Mengru L, Wei W. Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images. BMC Med Imaging 2021; 21:180. [PMID: 34836507 PMCID: PMC8626978 DOI: 10.1186/s12880-021-00711-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 11/17/2021] [Indexed: 12/24/2022] Open
Abstract
Background The objective of this study is to explore the value of two-dimensional (2D) and three-dimensional (3D) radiomics models based on enhanced computed tomography (CT) images in predicting BRCA gene mutations in patients with epithelial ovarian cancer. Methods The clinical and imaging data of 106 patients with ovarian cancer confirmed by surgery and pathology were retrospectively analyzed and genetic testing was performed. Radiomics features extracted from the 2D and 3D regions of interest of the patients’ primary tumor lesions were selected in the training set using the maximum correlation and minimum redundancy method. Then, the best features were selected through Lasso tenfold cross-validation. Feature subsets were employed to establish a radiomics model. The model’s performance was evaluated via area under the receiver operating characteristic curve analysis and its clinical validity was assessed by using the model’s decision curve. Results On the validation set, the area under the curve values of the 2D, 3D, and 2D + 3D combined models were 0.78 (0.61–0.96), 0.75 (0.55–0.92), and 0.82 (0.61–0.96), respectively. However, the DeLong test P values between the three pairs of models were all > 0.05. The decision curve analysis showed that the radiomics model had a high net benefit across all high-risk threshold probabilities. Conclusions The three radiomics models can predict the BRCA gene mutation in ovarian cancer, and there were no statistically significant differences between the prediction performance of the three models.
Collapse
Affiliation(s)
- Liu Mingzhu
- Division of Life Sciences and Medicine, The First Affiliated Hospital of University of Science and Technology of China, University of Science and Technology of China, Hefei, 230031, Anhui, China
| | - Ge Yaqiong
- GE Healthcare China, Pudong New Area, No.1 Huatuo Road, Shanghai, 210000, China
| | - Li Mengru
- Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230031, Anhui, China
| | - Wei Wei
- Department of Radiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, Anhui, China.
| |
Collapse
|
30
|
Li Q, Che F, Wei Y, Jiang HY, Zhang Y, Song B. Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Rev Gastroenterol Hepatol 2021; 15:1267-1279. [PMID: 34452581 DOI: 10.1080/17474124.2021.1974294] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Intrahepatic cholangiocarcinoma is the second most common liver cancer. Desmoplastic stroma may be revealed as distinctive histopathologic findings favoring intrahepatic cholangiocarcinoma. Meanwhile, a range of imaging manifestations is often accompanied with rich desmoplastic stroma in intrahepatic cholangiocarcinoma, which can indicate large bile duct ICC, and a higher level of cancer-associated fibroblasts with poor prognosis and weak treatment response. AREAS COVERED We provide a comprehensive review of current state-of-the-art and recent advances in the imaging evaluation for diagnosis, staging, prognosis and treatment response of intrahepatic cholangiocarcinoma. In addition, we discuss precursor lesions, cells of origin, molecular mutation, which would cause the different histological classification. Moreover, histological classification and tumor microenvironment, which are related to the proportion of desmoplastic stroma with many imaging manifestations, would be also discussed. EXPERT OPINION The diagnosis, prognosis, treatment response of intrahepatic cholangiocarcinoma may be revealed as the presence and the proportion of desmoplastic stroma with a range of imaging manifestations. With the utility of radiomics and artificial intelligence, imaging is helpful for ICC evaluation. Multicentre, large-scale, prospective studies with external validation are in need to develop comprehensive prediction models based on clinical data, imaging findings, genetic parameters, molecular, metabolic, and immune biomarkers.
Collapse
Affiliation(s)
- Qian Li
- Department of Radiology, Sichuan University West China Hospital, Chengdu, China
| | - Feng Che
- Department of Radiology, Sichuan University West China Hospital, Chengdu, China
| | - Yi Wei
- Department of Radiology, Sichuan University West China Hospital, Chengdu, China
| | - Han-Yu Jiang
- Department of Radiology, Sichuan University West China Hospital, Chengdu, China
| | - Yun Zhang
- Department of Radiology, Sichuan University West China Hospital, Chengdu, China
| | - Bin Song
- Department of Radiology, Sichuan University West China Hospital, Chengdu, China
| |
Collapse
|
31
|
Xu H, Lv W, Zhang H, Ma J, Zhao P, Lu L. Evaluation and optimization of radiomics features stability to respiratory motion in 18 F-FDG 3D PET imaging. Med Phys 2021; 48:5165-5178. [PMID: 34085282 DOI: 10.1002/mp.15022] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 04/18/2021] [Accepted: 05/25/2021] [Indexed: 12/31/2022] Open
Abstract
PURPOSE To evaluate the impact of respiratory motion on radiomics features in 18 F-fluoro-2-deoxy-D-glucose three dimensional positron emission tomography (18 F-FDG 3D PET) imaging and optimize feature stability by combining preprocessing configurations and aggregation strategies. METHODS An in-house developed respiratory motion phantom was imaged in 3D PET scanner under nine respiratory patterns including one reference pattern. In total, 487 radiomics features were extracted for each respiratory pattern. Feature stability to respiratory motion was first evaluated by metrics of coefficient of variation (COV) and relative difference (RD) in a fixed preprocessing configuration. Further, one-way ANOVA and trend analysis were performed to evaluate the impact of preprocessing configuration (voxel size, discretization scheme) and aggregation strategy on feature stability. Finally, an optimization framework was proposed by selected feature-specific configurations with minimum COV value, and the diagnostic performance was validated in stable versus unstable features and fixed versus optimal features by a set of 46 patients with lung disease. RESULTS PET radiomics features were sensitive to respiratory motion, only 79/487 (16%) features were identified to be very stable in the fixed configuration. Preprocessing configuration and aggregation strategy had an impact on feature stability. For different voxel size, bin number, bin size and aggregation strategy, 188/487 (39%), 70/487 (15%), 148/487 (30%), and 38/95 (29%) features appeared significant changes in feature stability. The optimized configuration had the potential to improve feature stability compared to fixed configuration, with the COV decreased from 22% ±24% to 16% ±20%. Regarding the diagnostic performance, the stable and optimal configuration features outperformed the unstable and fixed configuration features, respectively (AUC 0.88, 0.87 vs. 0.83, 0.85). CONCLUSIONS Respiratory motion shows considerable impact on feature stability in 3D PET imaging, while optimizing preprocessing configuration may improve feature stability and diagnostic performance.
Collapse
Affiliation(s)
- Hui Xu
- School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, China.,Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, China
| | - Wenbing Lv
- School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, China.,Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, China
| | - Hongyan Zhang
- School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, China.,Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, China
| | - Jianhua Ma
- School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, China.,Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, China
| | - Peng Zhao
- National Innovation Center for Advanced Medical Devices, Shenzheng, China
| | - Lijun Lu
- School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University, Guangzhou, China.,Guangdong Province Engineering Laboratory for Medical Imaging and Diagnostic Technology, Southern Medical University, Guangzhou, China
| |
Collapse
|
32
|
TCGA-TCIA-Based CT Radiomics Study for Noninvasively Predicting Epstein-Barr Virus Status in Gastric Cancer. AJR Am J Roentgenol 2021; 217:124-134. [PMID: 33955777 DOI: 10.2214/ajr.20.23534] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE. The purpose of this study was to investigate the value of TCGA-TCIA (The Cancer Genome Atlas and The Cancer Imaging Archive)-based CT radiomics for noninvasive prediction of Epstein-Barr virus (EBV) status in gastric cancer (GC). MATERIALS AND METHODS. A total of 133 patients with pathologically confirmed GC (94 in the training cohort and 39 in the validation cohort) who were identified from the TCGA-TCIA public data repository and two hospitals were retrospectively enrolled in the study. Two-dimensional and 3D radiomics features were extracted to construct corresponding radiomics signatures. Then, 2D and 3D nomograms were built by combining radiomics signatures and clinical information on the basis of multivariable analysis. Their performance and clinical practicability were determined, validated, and compared with respect to discrimination, calibration, reclassification, and time spent on tumor segmentation. RESULTS. Both 2D and 3D nomograms were robust and showed good calibration. The AUCs of the 2D and 3D nomograms showed no significant difference in the training cohort (0.919 vs 0.945, respectively; p = .41) or validation cohort (0.939 vs 0.955, respectively; p = .71). The net reclassification index showed that the 3D nomogram revealed no significant improvement in risk reclassification when compared with the 2D nomogram in the training cohort (net reclassification index, 0.68%; p = .14) and the validation cohort (net reclassification index, 6.06%; p = .08). Of note, the time spent on 3D segmentation (median, 907 seconds) was higher than that spent on 2D segmentation (median, 129 seconds). CONCLUSION. The 2D and 3D radiomics nomograms might have the potential to be used as effective tools for prediction of EBV in GC. When time spent on segmentation is considered, the 2D nomogram is more highly recommended for clinical application.
Collapse
|
33
|
Lee SH, Cho HH, Kwon J, Lee HY, Park H. Are radiomics features universally applicable to different organs? Cancer Imaging 2021; 21:31. [PMID: 33827699 PMCID: PMC8028225 DOI: 10.1186/s40644-021-00400-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 03/26/2021] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Many studies have successfully identified radiomics features reflecting macroscale tumor features and tumor microenvironment for various organs. There is an increased interest in applying these radiomics features found in a given organ to other organs. Here, we explored whether common radiomics features could be identified over target organs in vastly different environments. METHODS Four datasets of three organs were analyzed. One radiomics model was constructed from the training set (lungs, n = 401), and was further evaluated in three independent test sets spanning three organs (lungs, n = 59; kidneys, n = 48; and brains, n = 43). Intensity histograms derived from the whole organ were compared to establish organ-level differences. We constructed a radiomics score based on selected features using training lung data over the tumor region. A total of 143 features were computed for each tumor. We adopted a feature selection approach that favored stable features, which can also capture survival. The radiomics score was applied to three independent test data from lung, kidney, and brain tumors, and whether the score could be used to separate high- and low-risk groups, was evaluated. RESULTS Each organ showed a distinct pattern in the histogram and the derived parameters (mean and median) at the organ-level. The radiomics score trained from the lung data of the tumor region included seven features, and the score was only effective in stratifying survival for other lung data, not in other organs such as the kidney and brain. Eliminating the lung-specific feature (2.5 percentile) from the radiomics score led to similar results. There were no common features between training and test sets, but a common category of features (texture category) was identified. CONCLUSION Although the possibility of a generally applicable model cannot be excluded, we suggest that radiomics score models for survival were mostly specific for a given organ; applying them to other organs would require careful consideration of organ-specific properties.
Collapse
Affiliation(s)
- Seung-Hak Lee
- Departement of Electronic Electrical and Computer Engineering, Sungkyunkwan University, Suwon, 16419, South Korea
- Center for Neuroscience Imaging Research, Institute for Basic Science (IBS), Suwon, 16419, South Korea
- Core Research & Development Center, Korea University Ansan Hospital, Ansan, 15355, South Korea
| | - Hwan-Ho Cho
- Departement of Electronic Electrical and Computer Engineering, Sungkyunkwan University, Suwon, 16419, South Korea
- Center for Neuroscience Imaging Research, Institute for Basic Science (IBS), Suwon, 16419, South Korea
| | - Junmo Kwon
- Departement of Electronic Electrical and Computer Engineering, Sungkyunkwan University, Suwon, 16419, South Korea
- Center for Neuroscience Imaging Research, Institute for Basic Science (IBS), Suwon, 16419, South Korea
| | - Ho Yun Lee
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, South Korea.
- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, 06351, South Korea.
| | - Hyunjin Park
- Center for Neuroscience Imaging Research, Institute for Basic Science (IBS), Suwon, 16419, South Korea.
- School of Electronic and Electrical Engineering, Center for Neuroscience Imaging Research, Sungkyunkwan University, Suwon, 16419, South Korea.
| |
Collapse
|
34
|
A combined radiomics and clinical variables model for prediction of malignancy in T2 hyperintense uterine mesenchymal tumors on MRI. Eur Radiol 2021; 31:6125-6135. [PMID: 33486606 DOI: 10.1007/s00330-020-07678-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 12/08/2020] [Accepted: 12/29/2020] [Indexed: 12/18/2022]
Abstract
OBJECTIVE This study aims to develop a machine learning model for prediction of malignancy in T2 hyperintense mesenchymal uterine tumors based on T2-weighted image (T2WI) features and clinical information. METHODS This retrospective study included 134 patients with T2 hyperintense uterine mesenchymal tumors (104 patients in training cohort and 30 in testing cohort). A total of 960 radiomics features were initially computed and extracted from each 3D segmented tumor depicting on T2WI. The support vector machine (SVM) classifier was applied to build computer-aided diagnosis (CAD) models by using selected clinical and radiomics features, respectively. Finally, an observer study was conducted by comparing with two radiologists to evaluate the diagnostic performance. The area under the receiver operating characteristic (ROC) curve (AUC) was computed to assess the performance of each model. RESULTS Comparing with the T2WI-based radiomics model (AUC: 0.76 ± 0.09) and the clinical model (AUC: 0.79 ± 0.09), the combined model significantly improved the AUC value to 0.91 ± 0.05 (p < 0.05). The clinical-radiomics combined model yielded equivalent or higher performance than two radiologists (AUC: 0.78 vs. 0.91, p = 0.03; 0.90 vs.0.91, p = 0.13). There was a significant difference between the AUC values of two radiologists (p < 0.05). CONCLUSIONS It is feasible to predict malignancy risk of T2 hyperintense uterine mesenchymal tumors by combining clinical variables and T2WI-based radiomics features. Machine learning-based classification model may be useful to assist radiologists in decision-making. KEY POINTS • Radiomics approach has the potential to distinguish between benign and malignant mesenchymal uterine tumors. • T2WI-based radiomics analysis combined with clinical variables performed well in predicting malignancy risk of T2 hyperintense uterine mesenchymal tumors. • Machine learning-based classification model may be useful to assist radiologists in characterization of a T2 hyperintense uterine mesenchymal tumor.
Collapse
|
35
|
Caballo M, Pangallo DR, Sanderink W, Hernandez AM, Lyu SH, Molinari F, Boone JM, Mann RM, Sechopoulos I. Multi-marker quantitative radiomics for mass characterization in dedicated breast CT imaging. Med Phys 2020; 48:313-328. [PMID: 33232521 PMCID: PMC7898616 DOI: 10.1002/mp.14610] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 09/07/2020] [Accepted: 11/16/2020] [Indexed: 12/11/2022] Open
Abstract
Purpose To develop and evaluate the diagnostic performance of an algorithm for multi‐marker radiomic‐based classification of breast masses in dedicated breast computed tomography (bCT) images. Methods Over 1000 radiomic descriptors aimed at quantifying mass and border heterogeneity, morphology, and margin sharpness were developed and implemented. These included well‐established texture and shape feature descriptors, which were supplemented with additional approaches for contour irregularity quantification, spicule and lobe detection, characterization of degree of infiltration, and differences in peritumoral compartments. All descriptors were extracted from a training set of 202 bCT masses (133 benign and 69 malignant), and their individual diagnostic performance was investigated in terms of area under the receiver operating characteristics (ROC) curve (AUC) of single‐feature‐based linear discriminant analysis (LDA) classifiers. Subsequently, the most relevant descriptors were selected through a multiple‐step feature selection process (including stability analysis, statistical significance, evaluation of feature interaction, and dimensionality reduction), and used to develop a final LDA radiomic model for classification of benign and malignant masses, which was then tested on an independent test set of 82 cases (45 benign and 37 malignant). Results The majority of the individual radiomic descriptors showed, on the training set, an AUC value deriving from a linear decision boundary higher than 0.65, with the lower limit of the associated 95% confidence interval (C.I.) not overlapping with random chance (AUC = 0.5). The final LDA radiomic model resulted in a test set AUC of 0.90 (95% C.I. 0.80–0.96). Conclusions The proposed multi‐marker radiomic approach achieved high diagnostic accuracy in bCT mass classification, using a radiomic signature based on different feature types. While future studies with larger datasets are needed to further validate these results, quantitative radiomics applied to bCT shows potential to improve the breast cancer diagnosis pipeline.
Collapse
Affiliation(s)
- Marco Caballo
- Department of Medical Imaging, Radboud University Medical Center, PO Box 9101, Nijmegen, 6500 HB, The Netherlands
| | - Domenico R Pangallo
- Department of Medical Imaging, Radboud University Medical Center, PO Box 9101, Nijmegen, 6500 HB, The Netherlands.,Biolab, Department of Electronics and Telecommunication, Politecnico di Torino, Torino, 10129, Italy
| | - Wendelien Sanderink
- Department of Medical Imaging, Radboud University Medical Center, PO Box 9101, Nijmegen, 6500 HB, The Netherlands
| | - Andrew M Hernandez
- Department of Radiology, University of California Davis, Sacramento, CA, 95817, USA
| | - Su Hyun Lyu
- Department of Biomedical Engineering, University of California Davis, Sacramento, CA, 95817, USA
| | - Filippo Molinari
- Biolab, Department of Electronics and Telecommunication, Politecnico di Torino, Torino, 10129, Italy
| | - John M Boone
- Department of Radiology, University of California Davis, Sacramento, CA, 95817, USA.,Department of Biomedical Engineering, University of California Davis, Sacramento, CA, 95817, USA
| | - Ritse M Mann
- Department of Medical Imaging, Radboud University Medical Center, PO Box 9101, Nijmegen, 6500 HB, The Netherlands
| | - Ioannis Sechopoulos
- Department of Medical Imaging, Radboud University Medical Center, PO Box 9101, Nijmegen, 6500 HB, The Netherlands.,Dutch Expert Center for Screening (LRCB), PO Box 6873, Nijmegen, 6503 GJ, The Netherlands
| |
Collapse
|
36
|
Zhong J, Hu Y, Si L, Jia G, Xing Y, Zhang H, Yao W. A systematic review of radiomics in osteosarcoma: utilizing radiomics quality score as a tool promoting clinical translation. Eur Radiol 2020; 31:1526-1535. [PMID: 32876837 DOI: 10.1007/s00330-020-07221-w] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 07/12/2020] [Accepted: 08/21/2020] [Indexed: 12/11/2022]
Abstract
OBJECTIVES To assess the methodological quality and risk of bias in radiomics studies investigating diagnosis, therapy response, and survival of patients with osteosarcoma. METHODS In this systematic review, literatures on radiomics in osteosarcoma were included and assessed for methodological quality through the radiomics quality score (RQS). The risk of bias and concern of application was assessed using the Quality Assessment of Diagnostic Accuracy Studies tool. A meta-analysis of studies focusing on predicting osteosarcoma response to neoadjuvant chemotherapy was performed. RESULTS Twelve radiomics studies exploring osteosarcoma were identified, and five were included in meta-analysis. The RQS reached an average of 20.4% (6.92 of 36) with good inter-rater agreement (ICC 0.95, 95% CI 0.85-0.99). Four studies validated results with an internal dataset, none of which used external dataset; one study was prospectively designed, and another one shared part of the dataset. The risk of bias and concern of application were mainly related to index test aspect. The meta-analysis showed a diagnostic odds ratio of 43.68 (95%CI 13.5-141.31) for predicting response to neoadjuvant chemotherapy with high heterogeneity and low methodological quality. CONCLUSIONS The overall scientific quality of included studies is insufficient; however, radiomics remains a promising technology for predicting treatment response, which might guide therapeutic decision-making and related to prognosis. Improvements in study design, validation, and open science needs to be made to demonstrate the generalizability of findings and to achieve clinical applications. Widespread application of RQS, pre-trained RQS scoring procedure, and modification of RQS in response to clinical needs are necessary. KEY POINTS • Limited radiomics studies were established in osteosarcoma with mean RQS of 20.4%, commonly due to unvalidated results, retrospective study design, and absence of open science. • Meta-analysis of radiomics studies predicting osteosarcoma response to neoadjuvant chemotherapy showed high diagnostic odds ratio 43.68, while high heterogeneity and low methodological quality were the main concerns. • A previously trained data extraction instrument allowed reaching moderate inter-rater agreement in RQS applications, while RQS still needs improvement to become a wide adaptive tool in reviews of radiomics studies, in routine self-check before manuscript submitting and in study design.
Collapse
Affiliation(s)
- Jingyu Zhong
- Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai, 200050, China
| | - Yangfan Hu
- Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, No. 600 Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Liping Si
- Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai, 200050, China
| | - Geng Jia
- Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, No. 600 Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Yue Xing
- Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, No. 600 Yishan Road, Xuhui District, Shanghai, 200233, China
| | - Huan Zhang
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, 200025, China.
| | - Weiwu Yao
- Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai, 200050, China.
| |
Collapse
|